Handbook of Cancer and Immunology

Professor Nima Rezaei gained his medical degree (MD) from Tehran University of Medical Sciences and subsequently obtained an MSc in Molecular and Genetic Medicine and a PhD in Clinical Immunology and Human Genetics from the University of Sheffield, UK. He also spent a short-term fellowship of Pediatric Clinical Immunology and Bone Marrow Transplantation in the Newcastle General Hospital.  Professor Rezaei is now the Full Professor of Immunology and Vice Dean of International Affairs, School of Medicine, Tehran University of Medical Sciences, and the co-founder and Head of the Research Center for Immunodeficiencies. He is also the founding President of Universal Scientific Education and Research Network (USERN). Prof. Rezaei has already been the Director of more than 50 research projects and has designed and participated in several international collaborative projects. Prof. Rezaei is an editorial assistant or board member for more than 30 international journals. He has edited more than 30 international books, has presented more than 500 lectures/posters in congresses/meetings, and has published more than 1,000 scientific papers in the international journals.

T cell metabolism and its regulation by checkpoint molecules.- Tumor evasion of the immune system: the role of INF and TNF in cancer.- Intra-tumor cell heterogeneity: different immune responses for different cells.- Epithelial-mesenchymal plasticity, a link between inflammation and cancer metastasis.- Spatial technologies: a game changer to study tumor microenvironment.- Advances in tumor microenvironment immuneprofiling.- Immunodiagnostics: A perspective of tumor-specific antigen expression, specificity, and stability.- Immunohistochemistry as a tool to guide diagnosis, treatment, and prognosis in brain tumors.- Immune check point inhibitors and anti-angiogenic therapy for cancer.- Immune checkpoint inhibitors in unresectable hepatocellular carcinoma patients.- Synthetic-based Tumor-infiltrating lymphocytes (TILs) in adoptive cell therapies.- Development of next-generation antibody therapeutics using DDS and molecular imaging.- Immunotherapy for triple-negative breast cancer.- Immunotherapy for endocrine cancers.- Novel cancer treatment using oncolytic virus therapy.- Lysine acetylation inhibitors (KATi) as novel therapeutics.- CRISPR-Cas9 in personalized treatment in cancer.- Antibody-functionalized nanoparticles for targeted drug delivery in cancer therapy.- Challenges in computational pathology of biomarkers-driven predictive and prognostic immunotherapy.- Diagnosis and management of toxicities associated with immunotherapy in cancer.